Literature DB >> 7815500

Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines.

M J Hosie1, R Osborne, J K Yamamoto, J C Neil, O Jarrett.   

Abstract

Whole inactivated virus vaccines from the FL4 cell line protected against challenge with homologous feline immunodeficiency virus (Petaluma strain) but not against a heterologous FIV isolate (GL-8) which is distinct from the Petaluma strain in virus neutralization. Protection was associated with a type-specific neutralizing antibody response and was retained when the challenge virus was propagated in an unrelated cell line.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7815500      PMCID： PMC188698     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  17 in total

1.  Comparison of two host cell range variants of feline immunodeficiency virus.

Authors:  T R Phillips; R L Talbott; C Lamont; S Muir; K Lovelace; J H Elder
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

2.  Anti-cell antibody in macaques.

Authors:  E J Stott
Journal:  Nature       Date:  1991-10-03       Impact factor: 49.962

3.  Experimental vaccine protection against feline immunodeficiency virus.

Authors:  J K Yamamoto; T Okuda; C D Ackley; H Louie; E Pembroke; H Zochlinski; R J Munn; M B Gardner
Journal:  AIDS Res Hum Retroviruses       Date:  1991-11       Impact factor: 2.205

4.  Identification of conserved and variable regions in the envelope glycoprotein sequences of two feline immunodeficiency viruses isolated in Zurich, Switzerland.

Authors:  S Morikawa; H Lutz; A Aubert; D H Bishop
Journal:  Virus Res       Date:  1991-09       Impact factor: 3.303

5.  Productive infection of T-helper lymphocytes with feline immunodeficiency virus is accompanied by reduced expression of CD4.

Authors:  B J Willett; M J Hosie; T H Dunsford; J C Neil; O Jarrett
Journal:  AIDS       Date:  1991-12       Impact factor: 4.177

6.  Serological responses of cats to feline immunodeficiency virus.

Authors:  M J Hosie; O Jarrett
Journal:  AIDS       Date:  1990-03       Impact factor: 4.177

7.  Development of IL-2-independent feline lymphoid cell lines chronically infected with feline immunodeficiency virus: importance for diagnostic reagents and vaccines.

Authors:  J K Yamamoto; C D Ackley; H Zochlinski; H Louie; E Pembroke; M Torten; H Hansen; R Munn; T Okuda
Journal:  Intervirology       Date:  1991       Impact factor: 1.763

8.  Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats.

Authors:  J K Yamamoto; E Sparger; E W Ho; P R Andersen; T P O'Connor; C P Mandell; L Lowenstine; R Munn; N C Pedersen
Journal:  Am J Vet Res       Date:  1988-08       Impact factor: 1.156

9.  Molecular characterization and heterogeneity of feline immunodeficiency virus isolates.

Authors:  N Maki; T Miyazawa; M Fukasawa; A Hasegawa; M Hayami; K Miki; T Mikami
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

10.  Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.

Authors:  N C Pedersen; E W Ho; M L Brown; J K Yamamoto
Journal:  Science       Date:  1987-02-13       Impact factor: 47.728
View more
  28 in total

1.  Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus.

Authors:  M J Hosie; T Dunsford; D Klein; B J Willett; C Cannon; R Osborne; J Macdonald; N Spibey; N Mackay; O Jarrett; J C Neil
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

2.  Phylogenetic analyses of Texas isolates indicate an evolving subtype of the clade B feline immunodeficiency viruses.

Authors:  Eric A Weaver; Ellen W Collisson; Margaret Slater; Guan Zhu
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

3.  Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; D Del Mauro; I Lonetti; L Zaccaro; C Pollera; S Specter; M Bendinelli
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env.

Authors:  Margaret J Hosie; Dieter Klein; James M Binley; Thomas H Dunsford; Oswald Jarrett; James C Neil; Elzbieta Knapp; Simone Giannecchini; Donatella Matteucci; Mauro Bendinelli; James A Hoxie; Brian J Willett
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not confer protection.

Authors:  J N Flynn; C A Cannon; J C Neil; O Jarrett
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

6.  Evaluation of feline monocyte-derived dendritic cells loaded with internally inactivated virus as a vaccine against feline immunodeficiency virus.

Authors:  Giulia Freer; Donatella Matteucci; Paola Mazzetti; Francesca Tarabella; Valentina Catalucci; Enrica Ricci; Antonio Merico; Leonia Bozzacco; Mauro Pistello; Mauro Bendinelli
Journal:  Clin Vaccine Immunol       Date:  2008-01-23

7.  Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection.

Authors:  M J Hosie; J N Flynn
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

8.  Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; D Del Mauro; L Zaccaro; P Bandecchi; F Tozzini; M Bendinelli
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

9.  Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats.

Authors:  M Pistello; D Matteucci; G Cammarota; P Mazzetti; S Giannecchini; D Del Mauro; S Macchi; L Zaccaro; M Bendinelli
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies.

Authors:  M J Hosie; J N Flynn; M A Rigby; C Cannon; T Dunsford; N A Mackay; D Argyle; B J Willett; T Miyazawa; D E Onions; O Jarrett; J C Neil
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.